,Canonical_Smiles,drug_name,drug_type,Label
0,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O,Dinoprostone,19A-Inducer,negative
1,CC1(C)[C@@H](C=C(Cl)Cl)[C@H]1C(=O)OCc1cccc(Oc2ccccc2)c1,Permethrin,2B6-Inducer,positive
2,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,Ketoprofen,GST-Inhibitor,negative
3,O=c1[nH]cc(F)c(=O)[nH]1,Fluorouracil,-,negative
4,O=[P@]1(N(CCCl)CCCl)OCCCN1CCCl,trofosfamide,3A4-Substrate,negative
5,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,Dirithromycin,-,negative
6,CCCN(CCC)N=O,NN_dipropyl_nitrosoamine,2E1-Substrate,negative
7,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C,Lynestrenol,2C19-Inducer,negative
8,CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,Bumetanide,Solute_carrier_family_12_member_2-Inhibitor,negative
9,Cc1cc2ccccc2c2ccc3ccccc3c12,5_methylchrysene,2E1-Substrate,negative
10,O=NN(CCCl)C(=O)NC1CCCCC1,Lomustine,2D6-Substrate,negative
11,CC(Cc1ccccc1)N(C)Cc1ccccc1,Benzfetamine,-,negative
12,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O,Phenobarbital,2B6-Inducer,positive
13,CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,Posaconazole,UGT-Substrate,negative
14,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2,Galantamine,2D6-Substrate,negative
15,NC(=O)N1C(=O)C(=C(O)c2cccs2)c2cc(Cl)ccc21,Tenidap,Electrogenic_sodium_bicarbonate_cotransporter_1-Inhibitor,negative
16,CCOP(=S)(OCC)Oc1ccc([N+](=O)[O-])cc1,parathion,2E1-Substrate,negative
17,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],Nifedipine,2B6-Inducer,positive
18,Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1,Zalcitabine,P450_HFLA-Substrate,negative
19,Nc1ccc(Cc2ccc(N)c(Cl)c2)cc1Cl,MOCA,3A4-Substrate,negative
20,CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1,Difloxacin,-,negative
21,CO[C@H](C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1,Plicamycin,Methyltransferase-Inhibitor,negative
22,COc1cc([C@H]2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3O[C@@H]2CO)ccc1O,Silymarin,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
23,CCOC(=O)[C@@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,Enalapril,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
24,CC(C)(C)NC(=O)[C@@H]1C[C@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,Saquinavir,P450_HFLA-Substrate,negative
25,C=CCSSCC=C,diallylsulfide,2E1-Substrate,negative
26,CC(=O)C[C@H](c1ccccc1)c1c(O)c2ccccc2oc1=O,Warfarin,CP2CI-Substrate,negative
27,COc1ccc(C(c2ccc(OC)cc2)C(Cl)(Cl)Cl)cc1,methoxychlor,2C19-Substrate,negative
28,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D3,3A4-Substrate,negative
29,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Everolimus,-,negative
30,CCCO,Propanol,-,negative
31,N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O,Oxitriptan,Proton_coupled_amino_acid_transporter_1-Inhibitor,negative
32,O=S(Cc1ccccn1)c1nc2ccccc2[nH]1,Timoprazole,-,negative
33,CC(C=CC1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(=O)O,Alitretinoin,1A2-Inhibitor,negative
34,NC1=NC[C@@H]2c3ccccc3Cc3ccccc3N12,Epinastine,2D6-Inhibitor,negative
35,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Sufentanil,-,negative
36,C=CC#N,acrylonitrile,2E1-Substrate,negative
37,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,iloperidone,2D6-Substrate,negative
38,S=c1[nH]cnc2nc[nH]c12,Mercaptopurine,Solute_carrier_family_28_member_3-Substrate,negative
39,O=C1[C@@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,Ezetimibe,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
40,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,Phenoxymethylpenicillin,3A4-Inducer,negative
41,CN(C)CCN(Cc1ccccc1)c1ccccn1,Tripelennamine,2D6-Inhibitor,negative
42,CCO,Ethanol,4A11-Inducer,negative
43,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,Ursodeoxycholic Acid,2E1-Inducer,negative
44,CNCc1cc(=O)oc2cc(OC)ccc12,MMAMC,2D6-Substrate,negative
45,O=C1CN=C(c2ccccc2F)c2cc(Cl)ccc2N1CC(F)(F)F,2_oxo_quazepam,2C9-Substrate,negative
46,COc1cc2c(cc1OC)C(=O)[C@H](CC1CCN(Cc3ccccc3)CC1)C2,Donepezil,2D6-Substrate,negative
47,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Clopidogrel,-,negative
48,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,Dextromethorphan,2E1-Substrate,negative
49,CC(C)CCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_6,3A4-Substrate,negative
50,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,Sulpiride,-,negative
51,COc1ccc([C@H](CC(=O)O)N2CCN(CCCc3ccc4c(n3)NCCC4)C2=O)cn1,compound_A,2D6-Substrate,negative
52,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1,Reboxetine,2D6-Inducer,negative
53,[Hg],"Mercury, Metallic",4A11-Inhibitor,negative
54,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12,terbinafine,2C19-Substrate,negative
55,C[C@@H]1O[C@@]2(CS1)CN1CCC2CC1,SNI_2011_R_R,2D6-Substrate,negative
56,CCCC(C)Cn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_8,3A4-Substrate,negative
57,NC(N)=O,Carbamide,2E1-Inducer,negative
58,NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,Liothyronine,-,negative
59,COc1ccc2cc(CCC(C)=O)ccc2c1,nabumetone,2E1-Substrate,negative
60,CN(C)CCO[C@@](C)(c1ccccc1)c1ccccn1,Doxylamin,P450_HFLA-Inducer,negative
61,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Sirolimus,P450_HFLA-Substrate,negative
62,Cc1ccc(C(=O)[C@H](C)CN2CCCCC2)cc1,Tolperisone,2D6-Substrate,negative
63,CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O,Troleandomycin,CP2CI-Inhibitor,negative
64,Nc1ccc(C(=O)NCC(=O)O)cc1,Aminohippuric Acid,Solute_carrier_family_22_member_6-Substrate,negative
65,C[C@@H]1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,Argatroban,Methyltransferase-Inducer,negative
66,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,perhexiline,2D6-Substrate,negative
67,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Atazanavir,P450_HFLA-Inhibitor,negative
68,O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,Atovaquone,-,negative
69,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1,Niflumic Acid,Monocarboxylate_transporter_1-Inhibitor,negative
70,Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1,Pleconaril,P450_HFLA-Inducer,negative
71,Cn1c(N)nc2c3cccnc3ccc21,2_amino_3_methylimidazo_4_5_f_quinoline,1A2-Substrate,negative
72,COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,3_methylether_estradiol,2C19-Substrate,negative
73,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,Metandienone,3A4-Substrate,negative
74,CCN[C@H](C)Cc1ccc2c(c1)OCO2,MDE_R,2E1-Substrate,negative
75,CN[C@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,Frovatriptan,-,negative
76,CO[C@@H](CNC(=O)c1ccccc1OCC(=O)[O-])C[Hg]O,Sodium Salicylate,2E1-Inducer,negative
77,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,chlorpyrifos,2D6-Substrate,negative
78,CCC(C)C(=O)OC1CCC=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,Mevastatin,-,negative
79,C[C@H]1[C@H](NC(=O)C(=NOC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-],Aztreonam,P450_HFLA-Substrate,negative
80,CCOc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_ethoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
81,CNC(=O)ON=C(C)SC,Methomyl,-,negative
82,COC(=O)[C@H](c1ccccc1Cl)N1CCC2SC(=O)C=C2C1,2_oxo_clopidogrel,2D6-Substrate,negative
83,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,Oxymetazoline,UGT-Substrate,negative
84,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,Dihydroergotamine,-,negative
85,CN1CCN(CCCCN2C(=O)CN(N=Cc3ccc(-c4ccc(Cl)cc4)o3)C2=O)CC1,Azimilide,-,negative
86,Cc1ccc(O)cc1,p_cresol,2E1-Substrate,negative
87,CCn1cc(C(=O)O)c(=O)c2cnc(N3CCNCC3)nc21,Pipemidic acid,-,negative
88,COC1=CC(=O)OC1C(O)c1ccccc1Cl,Losigamone,-,negative
89,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1,Tirilazad,-,negative
90,CCN(CC)CCc1nc(-c2ccccc2)no1,Oxolamine,1B1-Inducer,negative
91,CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1,NE_100,2D6-Substrate,negative
92,CCCCCCCC(C)O,2_nonanol,2E1-Substrate,negative
93,N=C(N)NCCN1CCCCCCC1,Guanethidine,3A4-Inducer,negative
94,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,cinnarizine,2D6-Substrate,negative
95,COc1ccc(-c2nc3ccc(C4=NNC(=O)CC4C)cc3[nH]2)cc1,Pimobendan,-,negative
96,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,Triamcinolone,SUL-Inducer,negative
97,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Methyltestosterone,19A-Inducer,negative
98,Cc1cc(=O)oc2cc(O)ccc12,Hymecromone,UGT-Inhibitor,negative
99,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,Triamterene,1A2-Inhibitor,negative
100,C[C@@H](O)[C@@H]1NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,Octreotide,Canalicular_multispecific_organic_anion_transporter_1-Substrate,negative
101,CCN(C)N=O,NN_methyl_ethyl_nitrosoamine,2E1-Substrate,negative
102,CN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Chlorcyclizine,Multidrug_resistance_associated_protein_1-Substrate,negative
103,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,Buflomedil,2D6-Substrate,negative
104,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,9_cis_retinoic_acid,2C9-Substrate,negative
105,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,Pravastatin,Solute_carrier_organic_anion_transporter_family_member_1B1-Substrate,negative
106,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21,Enoxacin,-,negative
107,c1ccc2ncccc2c1,quinoline,2E1-Substrate,negative
108,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,Clomipramine,GST-Inhibitor,negative
109,CNC(=S)Oc1cc(C)c(SC)c(C)c1,methiocarb,2D6-Substrate,negative
110,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,Cyclobenzaprine,2D6-Substrate,negative
111,CCNc1nc(NC(C)(C)C)nc(SC)n1,terbutryn,2C19-Substrate,negative
112,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@](C)(F)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,Flurithromycin,-,negative
113,COc1ccc2c3c([nH]c2c1)C(C)=NCC3,harmaline,2D6-Substrate,negative
114,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,Lornoxicam,-,negative
115,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,Midazolam,P450_HFLA-Inhibitor,negative
116,CCn1nnc(C2=CCCN(C)C2)n1,LU_2509,2D6-Substrate,negative
117,CO[C@@]12CC[C@]3(C[C@H]1[C@](C)(O)C(C)(C)C)[C@@H]1Cc4ccc(O)c5c4[C@]3(CCN1CC1CC1)[C@@H]2O5,Buprenorphine,CP2CI-Substrate,negative
118,COc1ccc(CCNCCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,norverapamil_S,2C8-Substrate,negative
119,NN=O,Nitrosamine,-,negative
120,Cc1cc(Cl)c(S(N)(=O)=O)cc1S(N)(=O)=O,Disulfamide,-,negative
121,CC(=O)[C@@H]1CC[C@@H]2[C@H]3CCC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,Progesterone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
122,Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2,Tocopherol (vit E),2E1-Inhibitor,negative
123,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@@H]1c1cccc([N+](=O)[O-])c1,Barnidipine,2D6-Inhibitor,negative
124,Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1,Sulfadiazine,2E1-Substrate,negative
125,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,Pilocarpine,2E1-Substrate,negative
126,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,Etacrynic Acid,GST-Substrate,negative
127,CC(CF)NCC(O)COc1cccc2ccccc12,fluoro_propranolol,2D6-Substrate,negative
128,O=C1C(CCSc2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,sulfinpyrazone_sulfide,2C9-Substrate,negative
129,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,Meloxicam,-,negative
130,CCOP(=O)(OCC)Oc1ccc([N+](=O)[O-])cc1,Paraoxon,2E1-Substrate,negative
131,Cc1cccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1,Meclozin,1A2-Inhibitor,negative
132,CN[C@@]1(c2ccccc2Cl)CCCCC1=O,Ketamine,2D6-Substrate,negative
133,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,Letrozole,19A-Inhibitor,negative
134,CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@@H](CO)c1ccccc1)C2,Atropine,1A2-Inhibitor,negative
135,Cc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,dimemorfan,2D6-Substrate,negative
136,C#CCN(C)Cc1ccccc1,Pargyline,2E1-Inhibitor,negative
137,O=c1c(O)c(-c2ccccc2)oc2cc(O)cc(O)c12,galangin,2C9-Substrate,negative
138,COc1ccc2cc(C#N)c(=O)oc2c1,7_methoxy_3_cyano_coumarin,2E1-Substrate,negative
139,CN(C)C(=S)SSC(=S)N(C)C,Thiram,2B6-Inducer,positive
140,O=C(O)CCCC[C@@H]1CCSS1,Tioctic Acid,GST-Inducer,negative
141,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,Idebenone,1A2-Substrate,negative
142,CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1,Carbinoxamine,2E1-Substrate,negative
143,O=C1OC2(c3ccc(OCc4ccccc4)cc3Oc3cc(OCc4ccccc4)ccc32)c2ccccc21,dibenzyl_fluorescein,2D6-Substrate,negative
144,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F,Dutasteride,-,negative
145,CN1[C@H]2CCC[C@@H]1C[C@@H](NC(=O)c1nn(C)c3ccccc13)C2,Granisetron,2D6-Substrate,negative
146,C1CCC(C(C[C@H]2CCCCN2)C2CCCCC2)CC1,Perhexiline,2D6-Substrate,negative
147,Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,FLU,2C9-Substrate,negative
148,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,Tolcapone,Methyltransferase-Inhibitor,negative
149,O=C(NC1CCSC2CCCC(C(=O)O)N2C1=O)C(S)Cc1ccccc1,Omapatrilat,-,negative
150,OC(CNCC(F)(F)F)COc1cccc2ccccc12,N_trifluoro_ethyl_desisopropyl_propranolol,2D6-Substrate,negative
151,NC[C@@H](O)c1ccc(O)c(O)c1,Norepinephrine,19A-Inhibitor,negative
152,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,Valsartan,-,negative
153,Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C,Aminophenazone,CP2CI-Substrate,negative
154,C=CCN,Trastuzumab,19A-Inhibitor,negative
155,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,apigenin,1A2-Substrate,negative
156,CC(C)(C)NC[C@H](O)COc1cccc2c1CCC(=O)N2,Carteolol,2D6-Inhibitor,negative
157,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,Bosentan,Sodiumbile_acid_cotransporter-Inhibitor,negative
158,CC(O)(CC(=O)O)CC(=O)O,Meglutol,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
159,CCN(CC)c1cc(C)nc2ncnn12,Trapidil,-,negative
160,c1ccc2c(c1)Sc1ccccc1N2C[C@H]1CN2CCC1CC2,Mequitazine,2D6-Substrate,negative
161,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,Triazolam,P450_HFLA-Substrate,negative
162,Cc1c(F)c(N2CCN[C@@H](C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1,Grepafloxacin,-,negative
163,Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1,Bupranolol,2D6-Substrate,negative
164,CCCCCCCCC,nonane,2E1-Substrate,negative
165,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,Pazopanib,3A4-Inhibitor,negative
166,CC(C)C(C)NCC(O)COc1cccc2ccccc12,isopropyl_propranolol,2D6-Substrate,negative
167,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,Oxycodone,19A-Inhibitor,negative
168,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,Ranolazine,-,negative
169,N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,Tryptophan,1B1-Inducer,negative
170,Clc1ccc2nsnc2c1NC1=NCCN1,Tizanidine,1A2-Substrate,negative
171,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CCC2=O,Prasterone,19A-Substrate,negative
172,O=C(O)CC[C@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,tetranor,2C9-Substrate,negative
173,CNC(=O)Oc1cccc2c1OC(C)(C)C2,carbofuran,2D6-Substrate,negative
174,CO[C@H]1C=CO[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)C(C)=CC=C[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,Rifaximin,3A4-Inducer,negative
175,Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,Febuxostat,UGT-Substrate,negative
176,CC(CO)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,ipriflavone_M4,1A2-Substrate,negative
177,CCC(=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,Methadone,CP2CI-Substrate,negative
178,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,sibutramine,2C19-Substrate,negative
179,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,Lansoprazole,4A11-Inducer,negative
180,CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1,Pentoxyverine,2D6-Substrate,negative
181,CCN(CCO)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Hydroxychloroquine,2D6-Inhibitor,negative
182,Cc1ccccc1[C@H](OCCN(C)C)c1ccccc1,Orphenadrine (citrate),2D6-Inhibitor,negative
183,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,Chlorphenamine,Methyltransferase-Inducer,negative
184,CCOCC,Diethyl Ether,2E1-Inducer,negative
185,O=C(O)c1cc(N=Nc2ccc(O)c(C(=O)O)c2)ccc1O,Olsalazine,Methyltransferase-Inhibitor,negative
186,COc1c(N2CCN[C@@H](C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Gatifloxacin,-,negative
187,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,Piroxicam,-,negative
188,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,Oseltamivir,Solute_carrier_family_15_member_1-Substrate,negative
189,CC(C)n1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,fluvastatin,2D6-Substrate,negative
190,CCN[C@@H]1C[C@@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,Dorzolamide,2E1-Substrate,negative
191,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,Hydromorphone,2D6-Substrate,negative
192,CC12C=CC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,Boldenone,-,negative
193,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,Repaglinide,-,negative
194,O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-],Dipotassium clorazepate,-,negative
195,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,Ergometrine,-,negative
196,NCCCC(=O)O,Aminobutyric Acid,2D6-Substrate,negative
197,C#C[C@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)CC[C@H]4[C@H]3C(=C)C[C@]21CC,Etonogestrel,-,negative
198,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,Amiodarone,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
199,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,Hydrocodone,2D6-Substrate,negative
200,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO,Desoxycortone,Steroid_11_beta_hydroxylase-Substrate,negative
201,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Azithromycin,-,negative
202,CCNc1nc(Cl)nc(NC(C)C)n1,atrazine,2E1-Substrate,negative
203,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,Leflunomide,-,negative
204,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,Erlotinib,UGT-Inhibitor,negative
205,COc1cc(CNC(=O)CCCCC=CC(C)C)ccc1O,Capsaicin,2E1-Substrate,negative
206,CCCCCCNC(=N)NC(=N)N.Cl,Polihexanide,GST-Inhibitor,negative
207,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Cholic Acid,SUL-Substrate,negative
208,C[C@@H](O[C@@H]1OCCN(Cc2nc(=O)[nH][nH]2)[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,Aprepitant,P450_HFLA-Substrate,negative
209,CN1CCN2c3ccccc3Cc3ccccc3[C@H]2C1,Mianserin,2D6-Substrate,negative
210,O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1,Linopirdine,P450_HFLA-Substrate,negative
211,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vinblastine,2D6-Substrate,negative
212,CS(=O)(=O)OC[C@H](O)[C@H](O)COS(C)(=O)=O,Treosulfan,1A2-Inhibitor,negative
213,CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O,Aminogluthetimide,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inhibitor,negative
214,Cn1nnc2c(C(N)=O)ncn2c1=O,Temozolomide,Methyltransferase-Inhibitor,negative
215,C[C@@H]1NC(=O)[C@H](NC(=O)c2ncccc2O)[C@H](C)OC(=O)[C@@H](c2ccccc2)NC(=O)[C@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@H]2CCCN2C1=O,Virginiamycin,Methyltransferase-Inhibitor,negative
216,CCc1ccc([C@@H](C)CCc2ccc([N+](C)(C)C)cc2)cc1,Colestyramine,Sodiumbile_acid_cotransporter-Inducer,negative
217,CCOc1ccc(NC(C)=O)cc1,Phenacetin,2E1-Substrate,negative
218,CN1C(=O)OC(C)(C)C1=O,Trimethadione,2E1-Substrate,negative
219,CCC1(CC)C(=O)NC(=O)N(C)C1=O,Metharbital,1B1-Inducer,negative
220,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,Fluticasone,-,negative
221,C=C1CC[C@H](O)CC1=CC=C1CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,Colecalciferol,2D6-Inhibitor,negative
222,C[C@H](CN(C)C)CN1c2ccccc2S(=O)(=O)c2ccccc21,Oxomemazine,-,negative
223,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,thalidomide,2C19-Substrate,negative
224,CC(C)(C)NCC(O)COc1ccccc1C1CCCC1,Penbutolol,2D6-Substrate,negative
225,Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,Cidofovir,Solute_carrier_family_22_member_6-Substrate,negative
226,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)[C@@H]1c1cccc([N+](=O)[O-])c1,Manidipine,2D6-Inhibitor,negative
227,CN1C(=O)[C@H](O)N=C(c2ccccc2)c2cc(Cl)ccc21,Temazepam,-,negative
228,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,Tenoxicam,-,negative
